{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:45:11Z","timestamp":1793051111273,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.esmoop.2024.102387","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T17:11:31Z","timestamp":1708708291000},"page":"102387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203)"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9315-2158","authenticated-orcid":false,"given":"A.M.","family":"Di Giacomo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2645-6391","authenticated-orcid":false,"given":"M.","family":"Schenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1100-5264","authenticated-orcid":false,"given":"J.","family":"Medioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9812-0777","authenticated-orcid":false,"given":"S.","family":"Mandziuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9919-7485","authenticated-orcid":false,"given":"M.","family":"Majem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3127-1554","authenticated-orcid":false,"given":"G.","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cornfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3344-0948","authenticated-orcid":false,"given":"S.","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7742-1968","authenticated-orcid":false,"given":"T.","family":"Csoszi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2024.102387_bib1","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A\u00a0decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2024.102387_bib2","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","article-title":"The next decade of immune checkpoint therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2024.102387_bib3","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2024.102387_bib4","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.21.01497","article-title":"First-line immunotherapy for non\u2013small-cell lung cancer","volume":"40","author":"Reck","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.102387_bib5","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.3390\/cancers14071640","article-title":"The evolution of immune checkpoint inhibitors in advanced urothelial carcinoma","volume":"14","author":"Houssiau","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.esmoop.2024.102387_bib6","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.3390\/ijms21134691","article-title":"Immune checkpoint inhibitors in the treatment of renal cancer: current state and future perspective","volume":"21","author":"Lavacchi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.esmoop.2024.102387_bib7","article-title":"Preclinical characterization of MGA012, a novel clinical-stage PD-1 monoclonal antibody","volume":"5","author":"La Motte-Mohs","year":"2017","journal-title":"J\u00a0ImmunoTher Cancer"},{"issue":"suppl 13","key":"10.1016\/j.esmoop.2024.102387_bib8","article-title":"Pharmacodynamic correlates in a phase I study of INCMGA00012, a PD-1 antagonistic monoclonal antibody","volume":"79","author":"Condamine","year":"2019","journal-title":"Cancer Res"},{"issue":"suppl 13","key":"10.1016\/j.esmoop.2024.102387_bib9","article-title":"Assessment of flat dosing strategy for INCMGA00012 in patients with advanced tumors","volume":"79","author":"Chen","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2024.102387_bib10","article-title":"First-in-human phase 1 study of INCMGA00012 in patients with advanced solid tumors: interim results of the cohort expansion phase","volume":"6","author":"Mehnert","year":"2018","journal-title":"J\u00a0ImmunoTher Cancer"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2024.102387_bib11","first-page":"282","article-title":"A\u00a0phase 1 study of INCMGA00012, a PD-1 inhibitor, in patients with advanced solid tumors: preliminary results for patients with advanced cervical cancer (POD1UM-101)","volume":"7","author":"Mehnert","year":"2019","journal-title":"J\u00a0ImmunoTher Cancer"},{"key":"10.1016\/j.esmoop.2024.102387_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100529","article-title":"A\u00a0phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)","volume":"7","author":"Rao","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2024.102387_bib13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.102387_bib14","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.102387_bib15","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2024.102387_bib16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1158\/2326-6066.CIR-15-0193","article-title":"Phase I\/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab","volume":"4","author":"Weber","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.esmoop.2024.102387_bib17","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1\u2013selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2024.102387_bib18","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2024.102387_bib19","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non\u2013small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.102387_bib20","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2024.102387_bib21","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.102387_bib22","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2024.102387_bib23","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","article-title":"Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial","volume":"17","author":"Sharma","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.102387_bib24","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.20.02363","article-title":"Open-label, single-arm phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced clear cell renal cell carcinoma","volume":"39","author":"McDermott","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.102387_bib25","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2024.102387_bib26","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial","volume":"33","author":"Motzer","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.102387_bib27","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamaoncol.2018.4514","article-title":"Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial","volume":"5","author":"Ascierto","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2024.102387_bib28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2017.07.022","article-title":"Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma","volume":"86","author":"Hamid","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2024.102387_bib29","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1200\/JCO.19.01213","article-title":"Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer","volume":"38","author":"Vuky","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.102387_bib30","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/cncr.31043","article-title":"Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non\u2013small cell lung cancer: a systematic analysis of the literature","volume":"124","author":"Pillai","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2024.102387_bib31","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2024.102387_bib32","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40264-018-0774-8","article-title":"Safety and tolerability of immune checkpoint inhibitors (PD-1 and PD-L1) in cancer","volume":"42","author":"Baraibar","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.esmoop.2024.102387_bib33","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front Pharmacol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924001558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924001558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:33:02Z","timestamp":1761856382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924001558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2059702924001558"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.102387","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203)","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.102387","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"102387"}}